Use of glucometer and fasting blood glucose as screening tools for diabetes mellitus type 2 and glycated haemoglobin as clinical reference in rural community primary care settings of a middle income country by unknown
Muktabhant et al. BMC Public Health 2012, 12:349
http://www.biomedcentral.com/1471-2458/12/349RESEARCH ARTICLE Open AccessUse of glucometer and fasting blood glucose as
screening tools for diabetes mellitus type 2 and
glycated haemoglobin as clinical reference in
rural community primary care settings of a
middle income country
Benja Muktabhant1, Pattara Sanchaisuriya1, Pongdech Sarakarn2, Worawitaya Tawityanon3, Mantana Trakulwong3,
Songsri Worawat3 and Frank P Schelp4*Abstract
Background: Thailand is considered to be a middle income country, and to control and prevent type 2 diabetes
mellitus (T2DM) is one of the main concerns of the Thai Ministry of Public Health (MoPH). Screening for T2DM and
care for T2DM patients has been integrated into the primary health care system, especially in rural areas. The
intention of this investigation is to link public health research at the academic level with the local health authorities
of a district of a north-eastern province of the country.
Methods: Epidemiological methods were applied to validate the screening tools fasting capillary blood glucose
(CBG), measured by glucometer and venous blood for the determination of plasma glucose (VPG), used for
screening for T2DM among asymptomatic villagers. For assessing the validity of these two methods glycated
haemoglobin (HbA1c) values were determined and used as the ‘clinical reference’.
Results: All together 669 villagers were investigated. Determinations of CBG and VPG resulted in suspected T2DM
cases, with 7.3% when assessed by CBG and 6.4% by VPG using a cutoff point of 7 mmol/L (126 mg/dl). Taking
HbA1c determinations with a cutoff point of 7% into account, the proportion of T2DM suspected participants
increased to 10.4%. By estimating sensitivity, specificity and the positive predictive value of CBG and VPG against
the ‘clinical reference’ of HbA1c, sensitivity below 50% for both screening methods has been observed. The positive
predictive value was determined to be 58.5% for CBG and 56.8% for VPG. The specificity of the two screening tests
was over 96%.
Conclusions: The low sensitivity indicates that using fasting CBG or VPG as a screening tool in the field results in a
high proportion of diseased individuals remaining undetected. The equally low positive predictive values (below
60%) indicate a high working load for the curative sector in investigating suspected T2DM cases to determine
whether they are truly diseased or false positive cases according to the screening method. Further implications of
the results and the controversial discussion related to the use of HbA1c as clinical evidence for suffering from T2DM
are also discussed.
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It has been estimated that the proportion of diabetes
mellitus among adults between the ages of 20 and 79
was 6.4% in the year 2010 and will increase to 7.7% in
2030 world wide [1]. Sixty-nine percent of the increase
is expected to be in the so-called developing countries
and 20% in developed countries. The morbidity and
mortality pattern of the developed countries is now
highly prevalent in the low and middle income countries
as well, forcing the health delivery systems of these
countries to face the challenge of coping with the double
burden of infectious and chronic diseases [2]. One of the
major attempts to improve the health of the population
especially in the low and middle income countries has
been the primary health care attempt inaugurated at the
Alma Ata meeting over 30 years ago [3]. The focus dur-
ing the foregoing decades had been primarily laid on in-
fectious diseases and mother and child health care
(MCH), and Thailand has performed quite well in con-
trolling a number of important infectious diseases and
significantly improved MCH care [4,5]. However, there
has been an increase in the morbidity of chronic diseases
among the Thai population, in part due to the so-called
nutritional transition [6]. Intake of energy above require-
ments in connection with physical inactivity has resulted
in over nutrition and obesity of large portions of the
population, accompanied by the rapid development of
diabetes mellitus type 2 (T2DM). In Thailand, T2DM
ranks as number 8 for males and as number 2 for
females in the list of major diseases contributing to dis-
ability adjusted life years (DALY) [7]. Efforts to reduce
the spread of chronic diseases including primary and
secondary preventive measures nowadays have a high
priority and have been integrated into primary health
care by the Ministry of Public Health (MoPH), focusing
especially on T2DM.
In initiating screening for T2DM in the rural areas the
Ministry of Public Health (MoPH) has followed the
recommendation of the International Diabetes Federation
(IDF) which pointed out in a recent review the overall
benefits of screening and concluded that ‘individual coun-
tries should aim to develop and evaluate cost-effective
methods, setting up specific diabetes risk identification
and prevention strategies based on available resources’
[8].
In order to assist the efforts of the Ministry, the
authors decided to launch research activities in a rural
area of a province in the north-eastern part of the coun-
try (Nong Bua Lamphu Province) in co-operation with
the local health administration at the district and sub-
district levels. The Na Klang District of Nong Bua Lam-
phu Province, among other areas in Thailand, has been
selected as the site of a pilot project by the MoPH for an
initiative to assure the quality of primary health careespecially in the field of non-communicable diseases, fo-
cusing on the occurrence of some aspects of the meta-
bolic syndrome at the community level. It was not
intended to launch a strictly academic driven study but
to investigate a screening attempt on population basis
undertaken with limited resources by the district and
sub-district health officials. The results might cause the
health authorities to reconsider some of the measures
applied and by this improve the effectiveness of the
measures.
The specific objective of this study is to evaluate the
screening attempts for T2DM undertaken by the local
health authorities and to validate the screening tools
namely fasting capillary blood glucose (CBG) measure-
ment by glucometer kits and fasting plasma glucose
(VPG) determination, verified by glycated haemoglobin
(HbA1c) as the clinical reference.
Methods
Area of investigation
Nong Bua Lamphu Province is one province of the
Northeast of Thailand. The overall population density is
estimated to be 125 inhabitants/km2. The area is subdi-
vided into 6 districts with 59 sub-districts and 636 vil-
lages. Na Klang, the district selected for this study, has
an estimated total population of 91,000 inhabitants living
in 8 sub-districts with a total of 131 villages served by
13 primary care units (PCUs). From each PCU approxi-
mately 60 villagers participated; the total number of par-
ticipants tested was 669.
Routine district screening process
The attempts to control T2DM through screening are a
collaboration with the local health officials of the district
hospital and the staff of the PCUs. Screening for T2DM
is targeted towards the adult population aged 35 years
and older. Village health volunteers (VHVs) together
with the staff of the PCUs encourage the villagers in the
communities to participate in the screening program.
The district hospital serves as a referral institution to
verify screening results and assist in the treatment of the
disease and its complications.
The routine screening process undertaken by the dis-
trict health staff involves asking the target group to fast
overnight and then taking one CBG sample from the fin-
ger tip to assess glucose by glucometer (Accu Check
AdvantageW, Roche) and measuring blood pressure. Indi-
viduals found to have fasting blood glucose values of
≥7.0 mmol/L (≥126 mg/dl) are referred to the community
hospital for verification of the screening results. Verifica-
tion is done by analysis of one sample of fasting VPG
levels using the glucose oxidase method (Glucose Oxi-
dase Data Pro., Thermo ScientificW). In cases where the
verification via VPG produces a result of ≥7.0 mmol/L
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tient and cared for by the T2DM clinic set up by the dis-
trict hospital. However, individuals found, through the
CBG screening process, to have glucose values between
6.1 mmol/L (110 mg/dl) and 6.9 mmol/L (124 mg/dl) are
asked to come to the PCU after approximately 6 months
to be rechecked, using CBG again.The validation of the screening process
This study aimed to test the fasting CBG and VPG used
routinely against the reference value of HbA1c. For that
purpose, the routine method described above was fol-
lowed in principle, but amended slightly for the partici-
pants of this study.
All of the participating 13 PCUs were asked to recruit
approximately 60 villagers who had no previous T2DM
diagnosis. On the day screening took place in the re-
spective community either the staff of the PCUs or the
VHVs took blood from the fingertip for CBG determin-
ation by the glucometer kits. Immediately after that the
staff of the PCU drew 3 ml of venous blood for labora-
tory analysis. Blood was separated into two tubes: 1 ml
into a tube containing sodium fluoride for fasting blood
sugar and 2 ml into an EDTA tube for HbA1c determi-
nation. Tubes were stored not more than two hours before
being transferred to the laboratory. Plasma for fasting blood
sugar determinations was obtained by centrifugation and
stored at +40C until being analyzed using the glucose oxi-
dase method within two weeks. As the ultimate diagnostic
tool for the diagnosis of T2DM, glycated hemoglobin
(HbA1c) was determined by turbidimetric inhibition im-
munoassay (Kenolab™/T series; Thermo ScientificW), at the
laboratory of the district hospital. All HbA1c determina-
tions were done with only one newly purchased equip-
ment. Calibration and quality control measures were
strictly followed as recommended by the supplier of the
equipment. Sex and age of the participants were recorded
as well.Table 1 Number and percentage of villagers suspected to






CBG 669 49 7.3 5.5 – 9.6
VPG 669 43 6.4 4.7 – 8.6
HbA1c 656 68 10.4 8.2 – 13.0
*Number and proportion of villagers with fasting blood glucose levels of ≥7.0
mmol/L determined by glucometer and laboratory method as well as ≥7% for
HbA1c.
**C.I. Confidence interval.Data processing and statistical methods used
The data entered into an MS Excel spreadsheet by the
health officials of the district hospital of the participating
district were rearranged and revised by the staff of the
Department of Nutrition of the Faculty of Public Health,
Khon Kaen University. The data were then transferred
from the Excel program into a MINITAB Version 12
spreadsheet for further statistical evaluation. Ordinary
descriptive statistics were used for evaluating the data.
Sensitivity, specificity, positive (PPV) and negative pre-
dictive values (NPV) were calculated and the SPSS stat-
istical program Version 17 was used for modeling the
receiver operating characteristics (ROC curves).Ethical approval
Ethical approval was obtained from the ethical commit-
tee of the Khon Kaen University (HE 532243).
Results
Number, age and proportion of suspected DM cases
Alltogether 669 villagers from 13 PCUs participated in
the project. The ratio of females to males was 2.3, with
the average age of males being 53 and that of females
being significantly different at 48. The results of the
number and percentages of individuals suspected to have
DM is given in Table 1. Determinations of CBG and the
VPG resulted in similar percentages of suspected T2DM
cases, being 7.3% for the CBG and 6.4% for VPG. By tak-
ing HbA1c determination with a cutoff point of 7% into
account, the percentage of suspected T2DM cases
increases to 10.4%, a significant increase over the values
obtained by measuring fasting blood glucose using a cut-
off point of 7 mmol/L (126 mg/dl).
Validity of CBG and VPG results as screening tools versus
each other and HbA1c
The CBG determinations as screening tool and VPG as
reference with a cutoff point of 7 mmol/L (126 mg/dl),
resulted in a sensitivity of 81.4% and specificity of 97.8%
and a PPV of 71.4% (Table 2). When testing the values
obtained by CBG and VPG as screening method and
HbA1c values at a cutoff point of 7% as clinical refer-
ence, sensitivity decreased below 50% for both methods,
45.6% for CBG and 39.7% for VPG. Consequently, the
PPV also decreased to 58.5% for CBG and 56.8% for
VPG. Specificity of all the tests was over 96%.
Receiver operating characteristics (ROC) curves
The ROC curve with CBG values as the screening vari-
able and VPG values as the reference (positive actual
state 7.0 mmol/L (126 mg/dl)) is shown in Figure 1 and
the ROC curves with CBG and VPG as the screening
variables and HbA1c as the reference (positive actual
state 7%) are provided in Figure 2. Statistical indicators
for the interpretation of the three ROC curves are







Sensitivity Specificity PPV** NPV**
CBG VPG 669 35/43 (81.4%) 612/626 (97.8%) 35/49 (71.4%) 612/620 (98.7%)
CBG HbA1c 656 31/68 (45.6%) 566/588 (96.3%) 31/53 (58.5%) 566/603 (93.9%)
VPG HbA1c 645 25/63 (39.7%) 563/582 (96.7%) 25/44 (56.8%) 563/601 (93.7%)
*VPG ≥7.0 mmol/L and HbA1c ≥7%.
**PPV Positive predictive value, NPV Negative predictive value.
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ROC curves is 0.898, indicating that statistically the best
combination is VPG as reference with the CBG results
as the screening tool. The smaller area under the curve
for the case where HbA1c is the reference and VPG is
the screening tool is 0.733. Comparing the lower and
upper bounds of the 95% C.I., CBG as a screening tool
has a more narrow range (0.620 to 0.888) in comparison
to VPG (0.529 to 0.938), taking HbA1c as reference. Ac-
cording to the result of the ROC curves, optimal results
would be achieved with a cutoff point of 5.6 mmol/L
(101 mg/dl) taking CBG as the screening tool and the
VPG as the reference. Sensitivity in this case would be
75% and specificity 78.8%. Optimal cutoff point for
CBG would be 5.03 mmol/L (90.6 mg/dl) when taking
HbA1c as the reference (with a cutoff point of 7%).
Sensitivity would be then 85.7% and specificity 50%.
Using VPG as the screening tool, the optimal cutoff
point would be 4.6 mmol/L (82.9 mg/dl) when HbA1c
is the reference (cutoff point of 7%). The sensitivity inFigure 1 ROC curve with CBG values as screening variable and
VPG as reference (positive actual state 7.0 mmol/L). Original
calculation has been done with glucose concentration measured in
mg/dl.this case would also be 85.7%, but the specificity would
decrease to 26.2%.
Discussion
The population of the study area is genetically quite uni-
form and no different ethnic groups are living there.
Screening for T2DM takes place in a totally different en-
vironment in high income countries compared to coun-
tries in the category of low or middle income, such as
Thailand. So-called primary care in high income coun-
tries usually is a ‘passive’ service provided by the ambu-
latory care section of the health delivery system, in that
individuals are encouraged to see their general practi-
tioners in their clinic and they only undergo a test
according to the decision of the particular clinician they
consult. In Thailand the MoPH has initiated a more ac-
tive screening effort in rural areas, where the general
population is being approached by VHVs to assemble at
a central spot within their community after a nights fast-
ing to be screened by the staff of the PCU in charge ofFigure 2 ROC curve with CBG and VPG as screening
variables and HBA1c as reference (positive actual state 7%).
Original calculation has been done with glucose concentration
measured in mg/dl.
Table 3 Interpretation of ROC curves
VPG (Ref.) vs CBG HbA1c (Ref.) vs. CBG HbA1c (Ref.) vs. VPG
Positive state for ROC curve 7.0 mmol/L 7% 7%
No. positive 4 7 7
No. negative 665 634 634
Area under curve 0.898 0.754 0.733
Std.Err. 0.036 0.068 0.104










Optimal test result for 5.6 5.03 4.6
Sensitivity 75.0% 85.7% 85.7%
Specificity 100 – 21.2% 100 – 50.0% 100 – 73.8%
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advocates has to be easy to perform, must be time and
cost effective, and care has to be taken not to overload
the clinical arm of the health delivery system, such as
district and provincial hospitals, with a heavy load of
false positive cases indicated by a low PPV.
It is not feasible for the understaffed and overworked
health officials at the sub-district level to take more than
one CBG sample and come back to the same village
after about one week and take another sample. Also
supervision of the staff by their superiors from the pro-
vincial level is not possible when doubling the work.
Also, to actually relate the result from the first and the
second sample to one and the same individual needs ac-
curacy which cannot be always expected from a public
health nurse with a two years training let alone from a
VHV. Similarly, to conduct an oral glucose tolerance test
(OGTT) on a population basis is beyond feasibility. One
round in one district might involve testing more than
7,000 individuals in 119 villages.
This study attempted to follow the screening proce-
dures of the Thai health delivery service of the partici-
pating district as much as possible in order to evaluate
its achievements but also its constraints. According to
the study plan it was not intended to draw a representa-
tive sample of adults from the district. Still, the propor-
tion of individuals found to have fasting blood glucose
concentrations of 7 mmol/L (126 mg/dl) and above was
similar to the T2DM prevalence estimated in nationwide
surveys, which is reported to be 9.6%, with 4.8% newly
diagnosed cases in 2000 [9] and 6.7% in 2004 [10]. The
latter estimate was age standardized based on the Thai
national population. In 1995 a representative sample of
three districts of a neighboring province (Khon Kaen) of
the study area detected a prevalence of T2DM of 11.9%
with a 95% C.I. of 8.4 to 16.5 by using the OGTT [11].
This figure compares well to the proportion ofindividuals found in this study to have HbA1c levels of
7% and over, which is 10.4%.
Since this study is restricted to reporting the validity
of screening tests to detect T2DM diseased patients,
the proportion of Impaired Fasting Glucose (IFG), in
the range of 6.1 mmol/L (101 mg/dl) to 6.9 mmol/L
(124 mg/dl), has not been reported. As outlined in the
methodology section, in the real field situation indi-
viduals found to have fasting blood glucose levels of
6.1 mmol/L (101 mg/dl) to 6.9 mmol/L (124 mg/dl) are
advised by the staff to come to the nearest PCU in ap-
proximately 6 months to be rechecked, at which time it
may be assumed that they will have a fasting blood sugar
level over 7 mmol/L (126 mg/dl) if they are indeed early
T2DM cases. Since it is estimated that half of all indivi-
duals having T2DM in Thailand remain undetected [9],
the aim of the health authorities at this time is to concen-
trate clinical attention on those being found to already
have T2DM. Using fasting blood glucose with a cutoff
point of 7.0 mmol/L (126 mg/dl) as a valid test for the
diagnosis of T2DM is recommended by the World
Health Organization (WHO) [12]. Using CBG as a tool
for screening and VPG determinations as a final diag-
nosis results in a sensitivity of over 80%, a specificity of
over 95% and a PPV of 70%. Using CBG as a screening
indicator against VPG as standard, the results as far as
sensitivity, specificity and PPV are concerned seems to
be acceptable. According to the ROC curve of this in-
vestigation the optimal cutoff point would be 5.6 mmol/L
(101 mg/dl), which is in accordance with the findings
of Nitiyanant et al. [13], who recommended a cutoff
point between 5.6 mmol/L (101 mg/dl) and 6.0 mmol/L
(108 mg/dl) for the Thai population.
When CBG values are used as a screening tool and
VPG as a reference, less than 20% of those screened
remained with undetected T2DM. However, when
selecting HbA1c as the reference and CBG as the
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identified and the proportion of false negative results
increases to 41.5%. In the case where VPG is the screen-
ing tool and HbA1c is the reference, 60.3% of T2DM
cases are not identified and the curative center is un-
necessarily burdened with 43.2% of the cases, which are
false positives.
HbA1c was recommended as a diagnostic tool as far
back as 1976 by Koenig et al., [14,15] and its use has
increased over time in clinical settings in high income
countries. For example a survey undertaken in Ontario
(Canada) found that in 2005 HbA1c were determined in
approximately 500,000 individuals without diabetes and
for more than 480,000 cases with diagnosed diabetes
[16]. In the same year, 37% of the Ontario adults without
T2DM were tested by serum blood glucose and less than
1% of clinicians used the OGTT. The controversial dis-
cussion about the application of HbA1c for either screen-
ing or clinical diagnosis intensified after the American
Diabetes Association (ADA) and the European Associ-
ation for the Study of Diabetes recommended the use of
HbA1c to diagnose T2DM [17]. That recommendation
was included in the ADA’s suggestions [18]. Recently also
the IDF and WHO pointed towards HbA1c as diagnostic
tool for T2DM [19], recommending a cutoff point for the
diagnosis of less then 6.5%. Despite the widespread use of
HbA1c in clinical settings, different cutoff points were
recommended for the diagnosis of T2DM, besides ≥6.5%
from ADA and WHO [18,19] also ≥7% from other
sources, such as the recommendation of Davidson and
Schriger [20] based on reassessing 2,712 individuals
‘without diabetes history’ and the use of ≥7% by the New
York City A1c Registry [21]. The distribution of HbA1c
in a sample of 323 healthy Thai individuals determined
the 2.5 and the 97.5 percentiles to be 2.9 to 4.9% respect-
ively, with a mean VPG of 5.11 mmol/L (92.1 mg/dl)
[22]. The ROC curve for HbA1c as a reference with a 7%
cutoff point resulted in an optimal screening test of
5.03 mmol/L (90.1 mg/dl), which is similar to the above
quoted findings. However, the associated specificity of
50% would be unacceptable for the clinical settings. Des-
pite this the standard cutoff point set by the MoPH was a
VPG of 7 mmol/L (126 mg/dl) and it was against the ob-
jective of the study to overrule this.
The somehow ‘low’ prevalence of chronic diseases usu-
ally results in a low PPV indicating the burden of the col-
laborating hospitals to check a high number of individuals
with false positive results. In this situation a slight increase
in prevalence results in a remarkable increase in PPV.
That could have been achieved by selecting individuals
with a high risk of having T2DM, such as elevating the
cutoff point for age to 45 years and selecting only over
nourished and obese individuals as well as those with a
family history of T2DM for being eligible for screening.Again this was against the objective of the study since the
MoPH only excluded individuals with an age of <35 years
to be the target for screening. PPV also might increase
due to lowering the cutoff point of the clinical reference,
in this case from HbA1c values of ≥7% to ≥6.5% because
the lower cutoff point will increase the prevalence and by
this PPV. In fact a cutoff point of 6.5% HbA1c increases
PPV for CBG to 67.9% and VPG to 70.4% (unpublished
data).
Another important aspect however is to achieve an
optimal sensitivity of the screening method. Using
HbA1c ≥6.5% as cutoff point sensitivity for both screen-
ing indicators decreased, from 45.6% to 31.0% for CBG
and from 39.7% to 28.4% for VPG (unpublished data). It
might be argued that the low sensitivity by selecting
6.5% HbA1c as clinical reference is due to a high pro-
portion of screened individuals actually not having the
disease and consequently normal CBG and VPG values.
The intention was to increase the probability that the
clinical reference, here an HbA1c of 7% and above really
identify a diseased person.
According to the results of this study, the determin-
ation by CBG is better than determination of VPG, how-
ever, the fact remains that the associated sensitivity of
45% for CBG results is rather low, and it is even lower
for the VPG determinations.
Weighing the pros and cons of the use of HbA1c in
so-called ‘developing countries’, the authors of a recent
publication concluded that HbA1c should not be used
for the diagnosis of T2DM in these settings [23]. The
authors argued that the threshold for diagnosis, the cost
of the test, the absence of a standardization network and
the low sensitivity were all factors that make HbA1c an
inappropriate tool for T2DM diagnosis. As far Thailand
is concerned, HbA1c is often used in hospitals in moni-
toring T2DM in patients. Presently district and provin-
cial hospitals have equipment and financial means to
determine HbA1c correctly and each has a responsible
laboratory or will be included into a standardization net-
work. Therefore, a low sensitivity of CBG results in itself
might not be a sufficient argument against the use of
HbA1c as clinical reference in Thailand. Even in rural
Thailand, villagers are well aware of at least the essen-
tials of T2DM and know that blood glucose levels cor-
relate to dietary intake [24].
An additional argument against the indiscriminate use
of HbA1c is that the variation of the glycated
hemoglobin also depends on HbA1c variants and ethni-
city [25-28]. Other factors associated with plasma glu-
cose levels have been reviewed recently by Herman [29]
and Gomez-Perez et al. [23] and include anemia and
iron deficiency as well as abnormal hemoglobins. Test-
ing the applicability of HbA1c for Thai individuals as
reported above [22] did not suggest that the Thai
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HbA1c levels are concerned. However, the individuals
tested had been derived from a population in Bangkok
and not from a population of the Northeast of the coun-
try, where anemia and iron deficiency are common and
Thalassemia is a public health problem [30,31]. Haemo-
globin E (Hb E) is the most common trait for hemoglo-
binopathies prevalent in the Northeast of Thailand [32].
Adjusted HbA1c values were higher in a group of Asians
in comparison to white individuals with Impaired Glu-
cose Tolerance (IGT) but the adjusted HbA1c difference
was insignificant (5.78% versus 6% respectively) [29].
Erythrocytes are vulnerable in the Thalassemia disease
[33] and the decrease of the mean erythrocyte age falsely
lowers HbA1c test results [34]. Weak but significant dif-
ferences between HbA1c levels of ‘normal’ subjects and
hetero- as well as homo-zygote Hb E carriers have been
determined previously [35]. However, the median values
of HbA1c levels of the Hb E groups have been below the
so called ‘normal’ controls. Therefore, the high number
of false negative results when using HbA1c as clinical
reference and fasting plasma glucose levels as screening
test should not be due to the prevalence of thalassemia
and Hb E.
An additional hint that false negative screening results
against HbA1c might not be related to haematological
issues but might be an indication of the VPG inadequacy
as a screening tool is the result of a study undertaken
some years ago, close to the area where this investigation
has been based [11]. At that time (1995), HbA1c was
not used as a reference, rather OGTT was preferred,
with the cutoff point of 11.1 mmol/L (200 mg/dl), and
the screening tool was fasting blood glucose, with a cut-
off point of 7.8 mmol/L (140 mg/dl). These settings
resulted in a sensitivity of 43.7%, specificity 89.8% and
the PPV 37.8%. It seems that in the case of Thailand the
use of both HbA1c and OGTT as final diagnostic tools
results in similarly low sensitivities, as long as fasting
blood glucose measurement is applied as screening tool.
Chronic kidney diseases may also affect HbA1c levels
through increased blood urea nitrogen levels, causing
the formation of carbamylated haemoglobin which can-
not be differentiated in the determination from HbA1c
[36]. In a recent publication from Thailand the propor-
tion of T2DM patients with microalbuminuria was
found to be about 40% [37]. Therefore, it cannot be
excluded that some of the cases of undetected T2DM
within the population screened for this study may have
microalbuminuria. However, it is unlikely that un-
detected chronic kidney disease already developed to
such an extent that it could have influenced the level of
HbA1c.
It has been reported recently that HbA1c is insuffi-
cient to detect T2DM in the case of early diabetic status[38]. The present situation in Thailand mainly demands
the identification of those who have been suffering from
T2DM for quite some time already, so that this limita-
tion of HbA1c at the present time may be overlooked.
Further investigations are necessary to recognize the
reasons for the low sensitivity of the screening indica-
tors. It has been reported recently that a high proportion
of T2DM patients obviously do not feel comfortable to
admit that they do not follow the advice of health
personnel [39]. In general a Thai villager is quite well
informed about the basics of diabetes mellitus [24]. It
might well be that, in an ill attempt to have a favorable
screening result, participants might limit energy and
carbohydrate intake for a number of days before screen-
ing, since the event is arranged about a week in advance.
The failure to identify individuals with yet undetected
T2DM might be less a technical problem related to
HbA1c, CBG or VGP considering that a similar investi-
gation using OGTT as reference standard some years be-
fore resulted in a similarly insufficient VPG sensitivity
[11]. The underlying reason for the observed discrepan-
cies between VPG and a clinical standard, either being
OGTT or HbA1c, might be due to the fact that the villa-
gers can somehow influence the VPG, in reducing carbo-
hydrate and calorie intake before screening, but not the
latter tests. What the villagers may not be aware of is
that HbA1c values reflect the status of glucose levels
over approximately a three months period. In the con-
text of Thai culture, villagers may be sensitive about
being confronted by the health staff after being checked
and found with unfavorable results. Health promotion
experts might further investigate this phenomenon and
try to change the attitude of the villagers.
Conclusions
This study has shown that screening for T2DM using
fasting capillary or plasma glucose levels determined by
CBG and VPG, using HbA1c as the clinical reference,
results in a very low sensitivity. This indicates that over
50% of diseased T2DM cases are not detected by such
screening processes. Similar results were obtained by an
earlier study using OGTT as the clinical reference [11].
More studies are necessary to explore reasons for this
phenomenon. It is unrealistic to assume that OGTT will
be used by the clinicians instead of HbA1c until all the
possible implications have been sufficiently surveyed as
suggested by Gomez-Perez et al. [23], even in middle-
income countries such as Thailand.
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